

Appeal No. 2013-1409

UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT

SHIRE DEVELOPMENT LLC., SHIRE PHARMACEUTICAL
DEVELOPMENT INC., COSMO TECHNOLOGIES LIMITED,
and GIULIANI INTERNATIONAL LIMITED,

Plaintiffs-Appellees,

v.

WATSON PHARMACEUTICALS, INC. (now known as Actavis, Inc.),
WATSON LABORATORIES, INC. – FLORIDA, WATSON PHARMA, INC.,
(now known as Actavis Pharma, Inc.), and WATSON LABORATORIES, INC.,

Defendants-Appellants.

Appeal from the United States District Court for the Southern District of
Florida in No. 12-CV-60862, Judge Donald M. Middlebrooks.

CORRECTED BRIEF OF PLAINTIFFS-APPELLEES

EDGAR H. HAUG
JASON A. LIEF
ANDREW S. WASSON
NICHOLAS F. GIOVE
ELIZABETH MURPHY
JONATHAN A. HERSTOFF
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151

August 26, 2013

Attorneys for Plaintiffs-Appellees

CFAD EX. 1033
IPR2015-01093

CERTIFICATE OF INTEREST

As required by Federal Rule of Appellate Procedure 26.1 and Federal Circuit Rule 47.4, counsel for Plaintiffs-Appellees Shire Development LLC, Shire Pharmaceutical Development Inc., Cosmo Technologies Limited, and Nogra Pharma Limited (formerly known as Giuliani International Limited) certify the following:

1. The full name of every party represented by me is:

Shire Development LLC
Shire Pharmaceutical Development Inc.
Cosmo Technologies Limited
Nogra Pharma Limited (formerly known as Giuliani International Limited)

2. The name of the real parties in interest represented by me are:

Shire Development LLC
Shire Pharmaceutical Development Inc.
Cosmo Technologies Limited
Nogra Pharma Limited (formerly known as Giuliani International Limited)

3. All parent corporations and any publicly held companies that own 10 percent or more of the stock of the party represented by me are:

Shire Development LLC and Shire Pharmaceutical Development Inc. are wholly owned subsidiaries of Shire plc.

Cosmo Pharmaceuticals S.p.A. is the parent corporation of and owns 10 percent or more of the stock of Cosmo Technologies Limited.

Nogra S.A. is the parent corporation of Nogra Pharma Limited. Nogra Two S.A. is the parent corporation of Nogra S.A. MGG Trust and GG Trust are two irrevocable discretionary New York trusts that own Nogra Two S.A. Mr. Jay H. McDowell serves as trustee for both the MGG Trust and the GG Trust.

4. The names of all law firms and the partners and associates that have appeared for the party represented by me in the trial court or are expected to appear in this Court are:

Edgar H. Haug
Jason A. Lief
Mark P. Walters
Andrew S. Wasson
Nicholas F. Giove
Elizabeth Murphy
Jonathan A. Herstoff
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151
(212) 588-0800

Eric C. Christu
Joseph R. Englander
Daniel J. Barsky
SHUTTS & BOWEN LLP
525 Okeechobee Boulevard, Suite 1100
West Palm Beach, FL 33401
(561) 650-8556

William Barry Blum
Martin James Keane, Jr.
GENOVESE JOBLOVE & BATTISTA
100 SE 2nd Street, Suite 4400
Miami, FL 33131
(305) 349-2300

/s/ Nicholas F. Giove
Counsel for Appellees
August 26, 2013

TABLE OF CONTENTS

TABLE OF AUTHORITIES vi

GLOSSARY ix

CLAIM CONSTRUCTION x

STATEMENT OF RELATED CASES xii

STATEMENT OF THE ISSUES 1

STATEMENT OF THE CASE 2

STATEMENT OF THE FACTS 4

I. The Parties, the Disease, and the Drug 4

II. The '720 Patent 6

III. The Prosecution History of the '720 Patent 9

IV. The Watson Product 13

V. The District Court's Determination of Infringement 15

 A. Inner Lipophilic Matrix 15

 B. Outer Hydrophilic Matrix 19

 C. Other Limitations 20

SUMMARY OF THE ARGUMENT 21

ARGUMENT 23

I. There Was No Clear and Unmistakable Disavowal of Magnesium Stearate or Conventional Lubricants as the "Inner Lipophilic Matrix" 23

 A. The Plain Meaning of Claim 1(a) Includes Magnesium Stearate 24

 B. There Was No Disavowal in the Prosecution History of the '720 Patent 24

1.	The Passage Cited by Watson Does Not Constitute a Disavowal.....	25
2.	The Applicants Were Explaining What the Franco Reference Disclosed—Not Disavowing Claim Scope.....	27
3.	The Entire Prosecution History and Claim Amendments Contradict Watson’s Disavowal Argument	28
C.	Watson’s Own Shifting Expressions of What Was Disavowed Belie Any Claim of “Clear and Unmistakable” Disavowal.....	29
D.	The Magnesium Stearate in the Granules of the Watson Product Is Not Used as a Conventional Lubricant.....	30
II.	The District Court Correctly Refused to Read a Non-Existent “Separate and Distinct” Limitation into the Claims	32
A.	The Phrase “Separate and Distinct” Does Not Exist in the Intrinsic Record	32
B.	The Prosecution History/Prior Art Does Not Impose a “Separate and Distinct” Limitation	33
C.	Watson’s Construction Is Untenable and Ambiguous	36
III.	The District Court Correctly Determined that the Watson Product Contains an “Inner Lipophilic Matrix”	37
A.	Only the Magnesium Stearate in the Granules Constitutes the Inner Lipophilic Matrix	37
B.	The Claims Allow Other Excipients to Inhabit the Same Region Inhabited by the Inner and Outer Matrices.....	39
1.	Hydrophilic Excipients May Be Present in the Granules as “Other Excipients”	39
2.	The Applicants Did Not Disavow SSG as an “Other Excipient”.....	40

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.